1.
Sun YS, Zhao Z, Yang ZN, Xu F, Lu HJ, Zhu ZY, et al. Risk Factors and Preventions
of Breast Cancer. International journal of biological sciences. 2017;13(11):1387-97.
2.
Gotzsche PC, Jorgensen KJ. Screening for breast cancer with mammography. The
25
Cochrane database of systematic reviews. 2013(6):Cd001877.
3.
Baum M. Should routine screening by mammography be replaced by a more
selective service of risk assessment/risk management? Women's health (London, England).
2010;6(1):71-6.
4.
Pace LE, Keating NL. A systematic assessment of benefits and risks to guide breast
cancer screening decisions. Jama. 2014;311(13):1327-35.
5.
Boyd NF, Guo H, Martin LJ, Sun L, Stone J, Fishell E, et al. Mammographic density
and the risk and detection of breast cancer. The New England journal of medicine.
2007;356(3):227-36.
6.
Lee K, Kim H, Lee JH, Jeong H, Shin SA, Han T, et al. Retrospective observation
on contribution and limitations of screening for breast cancer with mammography in Korea:
detection rate of breast cancer and incidence rate of interval cancer of the breast. BMC
women's health. 2016;16(1):72.
7.
del Carmen MG, Halpern EF, Kopans DB, Moy B, Moore RH, Goss PE, et al.
Mammographic breast density and race. AJR American journal of roentgenology.
2007;188(4):1147-50.
8.
Li SP, Lin ZX, Jiang XY, Yu XY. Exosomal cargo-loading and synthetic exosome-
mimics as potential therapeutic tools. Acta pharmacologica Sinica. 2018;39(4):542-51.
26
9.
Fais S, O'Driscoll L, Borras FE, Buzas E, Camussi G, Cappello F, et al. Evidence-
Based Clinical Use of Nanoscale Extracellular Vesicles in Nanomedicine. ACS nano.
2016;10(4):3886-99.
10.
Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends.
The Journal of cell biology. 2013;200(4):373-83.
11.
Storz G. An expanding universe of noncoding RNAs. Science (New York, NY).
2002;296(5571):1260-3.
12.
Vickers KC, Sethupathy P, Baran-Gale J, Remaley AT. Complexity of microRNA
function and the role of isomiRs in lipid homeostasis. Journal of lipid research.
2013;54(5):1182-91.
13.
Neilsen CT, Goodall GJ, Bracken CP. IsomiRs--the overlooked repertoire in the
dynamic microRNAome. Trends in genetics : TIG. 2012;28(11):544-9.
14.
Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA.
MicroRNAs in body fluids--the mix of hormones and biomarkers. Nature reviews Clinical
oncology. 2011;8(8):467-77.
15.
Reid G, Kirschner MB, van Zandwijk N. Circulating microRNAs: Association with
disease and potential use as biomarkers. Critical reviews in oncology/hematology.
2011;80(2):193-208.
27
16.
Zaratiegui M, Irvine DV, Martienssen RA. Noncoding RNAs and gene silencing. Cell.
2007;128(4):763-76.
17.
Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell.
2009;136(2):215-33.
18.
Shen Y, Yu X, Zhu L, Li T, Yan Z, Guo J. Transfer RNA-derived fragments and tRNA
halves: biogenesis, biological functions and their roles in diseases. Journal of molecular
medicine (Berlin, Germany). 2018;96(11):1167-76.
19.
Wu W, Sun M, Zou GM, Chen J. MicroRNA and cancer: Current status and
prospective. International journal of cancer. 2007;120(5):953-60.
20.
Weiland M, Gao XH, Zhou L, Mi QS. Small RNAs have a large impact: circulating
microRNAs as biomarkers for human diseases. RNA biology. 2012;9(6):850-9.
21.
Schrauder MG, Strick R, Schulz-Wendtland R, Strissel PL, Kahmann L, Loehberg
CR, et al. Circulating micro-RNAs as potential blood-based markers for early stage breast
cancer detection. PloS one. 2012;7(1):e29770.
22.
Mishra S, Srivastava AK, Suman S, Kumar V, Shukla Y. Circulating miRNAs
revealed as surrogate molecular signatures for the early detection of breast cancer. Cancer
letters. 2015;369(1):67-75.
23.
Zhang K, Wang YW, Wang YY, Song Y, Zhu J, Si PC, et al. Identification of microRNA
28
biomarkers in the blood of breast cancer patients based on microRNA profiling. Gene.
2017;619:10-20.
24.
Jia Y, Chen Y, Wang Q, Jayasinghe U, Luo X, Wei Q, et al. Exosome: emerging
biomarker in breast cancer. Oncotarget. 2017;8(25):41717-33.
25.
Hannafon BN, Trigoso YD, Calloway CL, Zhao YD, Lum DH, Welm AL, et al. Plasma
exosome microRNAs are indicative of breast cancer. Breast cancer research : BCR.
2016;18(1):90.
26.
Kumar P, Kuscu C, Dutta A. Biogenesis and Function of Transfer RNA-Related
Fragments (tRFs). Trends in biochemical sciences. 2016;41(8):679-89.
27.
Guo L, Chen F. A challenge for miRNA: multiple isomiRs in miRNAomics. Gene.
2014;544(1):1-7.
28.
existing
Yu F, Pillman KA, Neilsen CT, Toubia J, Lawrence DM, Tsykin A, et al. Naturally
isoforms
of
miR-222
have
distinct
functions.
Nucleic
acids
research.
2017;45(19):11371-85.
29.
Dhahbi JM, Spindler SR, Atamna H, Boffelli D, Martin DI. Deep Sequencing of
Serum Small RNAs Identifies Patterns of 5' tRNA Half and YRNA Fragment Expression
Associated with Breast Cancer. Biomarkers in cancer. 2014;6:37-47.
30.
Gospodarowicz MK, Brierley JD, Wittekind C. TNM classification of malignant
29
tumours: John Wiley & Sons; 2017.
31.
Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al.
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer:
American Society of Clinical Oncology/College of American Pathologists clinical practice
guideline update. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology. 2013;31(31):3997-4013.
32.
Nakamura K, Kusama K, Bai R, Sakurai T, Isuzugawa K, Godkin JD, et al.
Induction of IFNT-Stimulated Genes by Conceptus-Derived Exosomes during the
Attachment Period. PloS one. 2016;11(6):e0158278.
33.
Kozomara A, Griffiths-Jones S. miRBase: annotating high confidence microRNAs
using deep sequencing data. Nucleic acids research. 2014;42(Database issue):D68-73.
34.
Chan PP, Lowe TM. GtRNAdb 2.0: an expanded database of transfer RNA genes
identified in complete and draft genomes. Nucleic acids research. 2016;44(D1):D184-9.
35.
Chan PP, Lowe TM. GtRNAdb: a database of transfer RNA genes detected in
genomic sequence. Nucleic acids research. 2009;37(Database issue):D93-7.
36.
Zerbino DR, Achuthan P, Akanni W, Amode MR, Barrell D, Bhai J, et al. Ensembl
2018. Nucleic acids research. 2018;46(D1):D754-d61.
37.
Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring
30
and therapeutics. A comprehensive review. EMBO molecular medicine. 2012;4(3):143-59.
38.
Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American
Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers
in breast cancer. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology. 2007;25(33):5287-312.
39.
Ambros V. The functions of animal microRNAs. Nature. 2004;431(7006):350-5.
40.
Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell.
2004;116(2):281-97.
41.
Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA
expression profiles classify human cancers. Nature. 2005;435(7043):834-8.
42.
Bartels CL, Tsongalis GJ. MicroRNAs: novel biomarkers for human cancer. Clinical
chemistry. 2009;55(4):623-31.
43.
Cloonan N, Wani S, Xu Q, Gu J, Lea K, Heater S, et al. MicroRNAs and their
isomiRs function cooperatively to target common biological pathways. Genome biology.
2011;12(12):R126.
44.
Llorens F, Banez-Coronel M, Pantano L, del Rio JA, Ferrer I, Estivill X, et al. A
highly expressed miR-101 isomiR is a functional silencing small RNA. BMC genomics.
2013;14:104.
31
45.
Salem O, Erdem N, Jung J, Munstermann E, Worner A, Wilhelm H, et al. The highly
expressed 5'isomiR of hsa-miR-140-3p contributes to the tumor-suppressive effects of miR140 by reducing breast cancer proliferation and migration. BMC genomics. 2016;17:566.
46.
Wu CW, Evans JM, Huang S, Mahoney DW, Dukek BA, Taylor WR, et al. A
Comprehensive
Approach
to
Sequence-oriented
IsomiR
annotation
(CASMIR):
demonstration with IsomiR profiling in colorectal neoplasia. BMC genomics. 2018;19(1):401.
47.
Feng YH, Tsao CJ. Emerging role of microRNA-21 in cancer. Biomedical reports.
2016;5(4):395-402.
48.
Yan LX, Huang XF, Shao Q, Huang MY, Deng L, Wu QL, et al. MicroRNA miR-21
overexpression in human breast cancer is associated with advanced clinical stage, lymph
node metastasis and patient poor prognosis. RNA (New York, NY). 2008;14(11):2348-60.
49.
Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, et al. A microRNA
expression signature of human solid tumors defines cancer gene targets. Proceedings of the
National Academy of Sciences of the United States of America. 2006;103(7):2257-61.
50.
Eissa S, Matboli M, Shehata HH. Breast tissue-based microRNA panel highlights
microRNA-23a and selected target genes as putative biomarkers for breast cancer.
Translational research : the journal of laboratory and clinical medicine. 2015;165(3):417-27.
51.
Li X, Liu X, Xu W, Zhou P, Gao P, Jiang S, et al. c-MYC-regulated miR-23a/24-2/27a
32
cluster promotes mammary carcinoma cell invasion and hepatic metastasis by targeting
Sprouty2. The Journal of biological chemistry. 2013;288(25):18121-33.
52.
Anderson P, Ivanov P. tRNA fragments in human health and disease. FEBS letters.
2014;588(23):4297-304.
53.
Olvedy M, Scaravilli M, Hoogstrate Y, Visakorpi T, Jenster G, Martens-Uzunova ES.
A comprehensive repertoire of tRNA-derived fragments in prostate cancer. Oncotarget.
2016;7(17):24766-77.
54.
Lee YS, Shibata Y, Malhotra A, Dutta A. A novel class of small RNAs: tRNA-derived
RNA fragments (tRFs). Genes & development. 2009;23(22):2639-49.
55.
Endzelins E, Berger A, Melne V, Bajo-Santos C, Sobolevska K, Abols A, et al.
Detection of circulating miRNAs: comparative analysis of extracellular vesicle-incorporated
miRNAs and cell-free miRNAs in whole plasma of prostate cancer patients. BMC cancer.
2017;17(1):730.
56.
Yanez-Mo M, Siljander PR, Andreu Z, Zavec AB, Borras FE, Buzas EI, et al.
Biological properties of extracellular vesicles and their physiological functions. Journal of
extracellular vesicles. 2015;4:27066.
57.
Soung YH, Nguyen T, Cao H, Lee J, Chung J. Emerging roles of exosomes in cancer
invasion and metastasis. BMB reports. 2016;49(1):18-25.
33
58.
Melo SA, Sugimoto H, O'Connell JT, Kato N, Villanueva A, Vidal A, et al. Cancer
exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis.
Cancer cell. 2014;26(5):707-21.
59.
Chevillet JR, Kang Q, Ruf IK, Briggs HA, Vojtech LN, Hughes SM, et al.
Quantitative and stoichiometric analysis of the microRNA content of exosomes. Proceedings
of the National Academy of Sciences of the United States of America. 2014;111(41):14888-93.
60.
Doyle LM, Wang MZ. Overview of Extracellular Vesicles, Their Origin, Composition,
Purpose, and Methods for Exosome Isolation and Analysis. Cells. 2019;8(7).
34
Figure Legends
Figure 1. Schematic overview of the study.
Figure 2. Comparison of normalized reads of 3 significantly upregulated small RNAs in the
validation cohort (*p < 0.01).
Figure 3. Comparison of IsomiR abundance in serum from BC patients (n=78) and cancer-free
individuals (n=72). The 5 most abundant forms of miRNA are presented in the Y axis. miR-215p (A), miR-23a-3p (B).
Figure 4. Diagnostic utility of 3 small RNAs for BC detection. Receiver operating characteristic
curve analysis (A), relative levels using small RNAs in BC patients and cancer-free individuals
(N) by BC stage (*p < 0.01) (B), relative levels using small RNAs in BC patients and N by BC
subtype (*p < 0.01) (C), relative levels using small RNAs in BC patients by IHC analysis in
patients with invasive BC (D), and comparison of diagnostic values among serum markers CEA
and CA15-3, and our constructed model (E).
Figure 5. Characterization of EVs isolated with an exosome isolation kit. TEM analysis of EVs
(A). Western blot analysis of exosomal markers CD9 and TSG101 (B). Contribution of
nanoparticles of EVs (C), and total concentration of each EV (D). ApoB as a marker of
lipoproteins by western blotting (E).
Figure 6. Expression of identified small RNAs in EVs derived from serum of 32 BC patients and
35
20 cancer-free individuals (N), and from cell culture media of 184-h TERT, MCF7, and MDAMB-231 (*p < 0.01).
7DEOHV DQG )LJXUHV
Table 1. Clinicopathological characteristics of participants.
Table 2. Significantly upregulated small RNAs in the serum of BC group compared to N group in both screening and validation phase.
Table 3. Diagnostic accuracy, sensitivity, and specificity for discriminating BC patients from cancer-free individuals.
Figure 1. Schematic overview of the study.
Figure 2. Comparison of normalized reads of 3 significantly upregulated small RNAs in validation cohort (*p < 0.01).
Figure 3. IsomiR abundance in serum compared between BC patients (n=78) and cancer-free individuals (n=72).
The 5 most abundant forms of miRNAs are presented in Y axis.
Figure 4. Diagnostic utility of 3 small RNAs for BC detection. Receiver operating characteristic curve analysis (A), relative levels
using small RNAs in BC patients and cancer-free individuals (N) by BC stage (*p < 0.01) (B), relative levels using small RNAs in BC
patients and N by BC subtype (*p < 0.01) (C)
Figure 4. Diagnostic utility of 3 small RNAs for BC detection. relative levels using small RNAs in BC patients by IHC analysis in
patients with invasive BC (D), and comparison of diagnostic values among serum markers CEA and CA15-3, and our constructed
model (E).
Figure 5. Characterization of EVs isolated with an exosome isolation kit. TEM analysis of EVs (A). Western blot analysis of exosomal
markers CD9 and TSG101 (B). Contribution of nanoparticles of EVs (C), and total concentration of each EV (D). ApoB as a marker of
lipoproteins by western blotting (E).
Figure 6. Expression of identified small RNAs in EVs derived from serum of 32 BC patients and 20 cancer-free individuals (N), and
from cell culture media of 184-h TERT, MCF7, and MDA-MB-231 (*p < 0.001, **p < 0.01).
...
論文の公開元へ
